Individualized mRNA cancer vaccine encoding a patient’s tumor-specific neoantigens. After intramuscular injection, antigen-presenting cells take up the mRNA, translate it, and present the resulting neoantigen peptides on MHC I and II, priming and expanding neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells to recognize and eliminate residual melanoma cells.